Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for previously treated multiple myeloma:
- Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma (2026) NICE technology appraisal guidance 1133
- Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (2024) NICE technology appraisal guidance 974
- Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (2023) NICE technology appraisal guidance 897
This page was last updated: